GT Biopharma, Inc. GTBP
are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products based
on our proprietary Tri-specific Killer Engager ("TriKE®"), and Tetra-specific Killer Engager ("Dual Targeting TriKE®")
fusion protein immune cell engager technology platforms. Our TriKE® and Dual Targeting TriKE® platforms generate proprietary
therapeutics designed to harness and enhance the cancer killing abilities of a patient's own natural killer cells ("NK cells").
Last close
5.46
2026-10-23
Market cap
$246.3M
2026-06-30 share count
52-week range
0.22 - 11.98
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield0.1%
Diluted EPS-6.68
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0 | $0 | — | $0 | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — | $0 | $0 |
| R&D | $3.5M | $5.8M | $6.5M | $8.8M | $9.6M | $485.0K | $1.7M | $9.1M | $1.1M | $975.0K |
| SG&A | $8.9M | $8.6M | $7.1M | $12.4M | $47.9M | $6.3M | $9.8M | $12.5M | $134.5M | $8.4M |
| Total operating expenses | — | — | $13.6M | $21.3M | $57.5M | — | $16.1M | $250.1M | $135.6M | $9.4M |
| Operating income | -$12.4M | -$14.4M | -$13.6M | -$21.3M | -$57.5M | -$6.8M | $16.1M | -$250.1M | -$135.6M | -$9.4M |
| Interest expense | $127.0K | — | $213.0K | $8.0K | $718.0K | $3.0M | $2.1M | $9.1M | $8.6M | $6.6M |
| Pre-tax income | — | — | — | — | — | — | -$38.6M | -$259.2M | -$144.2M | $9.8M |
| Income tax | — | — | — | — | — | — | $0 | $0 | $0 | $0 |
| Net income | -$28.4M | -$13.2M | -$7.6M | -$20.9M | -$58.0M | -$28.3M | -$38.6M | -$259.2M | -$144.2M | $9.8M |
| EPS, basic | -6.68 | -6.94 | -5.64 | -19.66 | -2.06 | — | — | -5.16 | -8.60 | 119.91 |
| EPS, diluted | -6.68 | -6.94 | -5.64 | -19.66 | -2.06 | -6.45 | -0.01 | -5.16 | -8.60 | 119.91 |
| Shares, diluted (wtd. avg.) | 5.5M | 1.9M | 1.3M | 1.1M | 28.2M | 4.4M | 3.4M | 50,240 | 16,769 | 81,460 |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $6.8M | $4.0M | $1.1M | $5.7M | $9.0M | $5.3M | $28.0K | $60.0K | $576.0K | $19.0K |
| Short-term investments | — | — | $12.9M | $10.8M | $23.0M | — | — | — | — | — |
| Total current assets | $8.1M | $4.2M | $14.1M | $16.6M | $32.2M | $5.7M | $274.0K | $90.0K | $576.0K | $21.0K |
| Property, plant and equipment | — | — | — | — | — | — | $0 | $35.0K | $6.0K | $4.0K |
| Total assets | $7.1M | $4.2M | $14.1M | $16.7M | $32.2M | $5.7M | $396.0K | $25.4M | $254.4M | $25.0K |
| Accounts payable | $748.0K | $3.9M | $4.3M | $3.1M | $8.2M | $2.2M | $1.9M | $1.8M | $2.5M | $2.1M |
| Total current liabilities | $2.3M | $5.9M | $6.6M | $4.9M | $10.3M | $35.1M | $19.7M | $14.0M | $2.7M | $18.9M |
| Total liabilities | $31.0M | — | $6.6M | $5.0M | $10.3M | — | $19.7M | $14.0M | $2.7M | $18.9M |
| Retained earnings | -$726.3M | -$695.2M | -$682.1M | -$674.5M | -$653.6M | -$595.8M | -$567.3M | -$528.7M | -$269.5M | -$124.6M |
| Total equity | -$25.9M | -$1.7M | $7.5M | $11.7M | $21.9M | -$29.4M | -$19.3M | $11.4M | $251.7M | -$18.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.9M | -$12.9M | -$8.9M | -$15.2M | -$15.6M | -$7.3M | -$3.7M | -$10.7M | -$5.4M | -$1.9M |
| Depreciation and amortisation | — | — | — | — | — | $0 | $4.0K | $7.0K | $2.0K | $1.0K |
| Stock-based compensation | $432.0K | $230.0K | — | $7.7M | $33.9M | $269.0K | $5.3M | $9.7M | $130.1M | $6.6M |
| Capital expenditure | — | — | — | — | — | — | $0 | $36.0K | $4.0K | $0 |
| Investing cash flow | — | $12.9M | -$2.0M | $12.1M | -$23.0M | $0 | $200.0K | -$36.0K | -$4.0K | $0 |
| Financing cash flow | $15.8M | $3.0M | $6.3M | -$224.0K | $42.3M | $12.5M | $3.4M | $10.2M | $6.0M | $1.9M |
| Dividends paid | $229.0K | — | — | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-031922.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | $0 | $0 | — | — | — | — | — |
| Gross profit | $0 | $0 | — | — | — | — | — | — | — | — |
| Net income | $9.8M | -$144.2M | -$259.2M | -$38.6M | -$28.3M | -$58.0M | -$20.9M | -$7.6M | -$13.2M | -$28.4M |
Recent filings and events
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Charter or fiscal year changed Item 5.03
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Accounts can no longer be relied on The company is telling investors that figures it has already published are wrong. Rare, and about as direct as a filing gets. Item 4.02
- Delisting notice Item 3.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder rights changed Item 3.03
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |